ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 224 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2022. The put-call ratio across all filers is 0.80 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $185,233,121 | -22.4% | 5,195,880 | +0.4% | 0.04% | -17.8% |
| Q2 2023 | $238,839,043 | +16.8% | 5,177,521 | +1.5% | 0.04% | +9.8% |
| Q1 2023 | $204,555,995 | -15.1% | 5,101,147 | -2.0% | 0.04% | -14.6% |
| Q4 2022 | $241,040,350 | -3.7% | 5,202,684 | -13.9% | 0.05% | -9.4% |
| Q3 2022 | $250,367,000 | -4.9% | 6,046,038 | +37.0% | 0.05% | 0.0% |
| Q2 2022 | $263,365,000 | +7.6% | 4,414,440 | +31.0% | 0.05% | +26.2% |
| Q1 2022 | $244,747,000 | +1.2% | 3,370,245 | +17.1% | 0.04% | +7.7% |
| Q4 2021 | $241,961,000 | +7.0% | 2,877,403 | +14.7% | 0.04% | +2.6% |
| Q3 2021 | $226,221,000 | +493.8% | 2,508,275 | +527.7% | 0.04% | +533.3% |
| Q2 2021 | $38,098,000 | -47.7% | 399,571 | -37.5% | 0.01% | -53.8% |
| Q1 2021 | $72,787,000 | -21.2% | 639,262 | -4.2% | 0.01% | -23.5% |
| Q4 2020 | $92,359,000 | +49.1% | 667,187 | -11.5% | 0.02% | +30.8% |
| Q3 2020 | $61,941,000 | +29.1% | 753,624 | +22.8% | 0.01% | +18.2% |
| Q2 2020 | $47,995,000 | +29.1% | 613,586 | -26.7% | 0.01% | +10.0% |
| Q1 2020 | $37,168,000 | -32.2% | 836,557 | -34.9% | 0.01% | -9.1% |
| Q4 2019 | $54,845,000 | -60.7% | 1,284,110 | -60.6% | 0.01% | -64.5% |
| Q3 2019 | $139,462,000 | -66.1% | 3,259,962 | -49.7% | 0.03% | -65.9% |
| Q2 2019 | $411,495,000 | -7.0% | 6,480,239 | +1.5% | 0.09% | -9.0% |
| Q1 2019 | $442,647,000 | +69.8% | 6,381,870 | +6.4% | 0.10% | +53.8% |
| Q4 2018 | $260,710,000 | -35.3% | 5,996,082 | +13.7% | 0.06% | -23.5% |
| Q3 2018 | $402,686,000 | -14.0% | 5,274,908 | -13.4% | 0.08% | -18.3% |
| Q2 2018 | $468,149,000 | +46.6% | 6,090,143 | -2.7% | 0.10% | +44.4% |
| Q1 2018 | $319,259,000 | +17.5% | 6,261,206 | +6.9% | 0.07% | +20.0% |
| Q4 2017 | $271,746,000 | +2.3% | 5,859,120 | +17.5% | 0.06% | -1.6% |
| Q3 2017 | $265,617,000 | -18.5% | 4,987,165 | -5.0% | 0.06% | -20.8% |
| Q2 2017 | $325,899,000 | +5.0% | 5,247,141 | +14.5% | 0.08% | +2.7% |
| Q1 2017 | $310,496,000 | -16.0% | 4,580,944 | -12.8% | 0.08% | -19.4% |
| Q4 2016 | $369,494,000 | +26.0% | 5,255,191 | +27.2% | 0.09% | +27.4% |
| Q3 2016 | $293,190,000 | +43.1% | 4,132,923 | -1.3% | 0.07% | +37.7% |
| Q2 2016 | $204,844,000 | -21.7% | 4,188,184 | +1.3% | 0.05% | -23.2% |
| Q1 2016 | $261,625,000 | +1.5% | 4,132,430 | +79.9% | 0.07% | +3.0% |
| Q4 2015 | $257,703,000 | +42.6% | 2,297,234 | +22.4% | 0.07% | +34.0% |
| Q3 2015 | $180,741,000 | +5.5% | 1,876,646 | +12.2% | 0.05% | +13.6% |
| Q2 2015 | $171,275,000 | +75.2% | 1,672,780 | +6.2% | 0.04% | +76.0% |
| Q1 2015 | $97,783,000 | +63.0% | 1,574,844 | +15.2% | 0.02% | +56.2% |
| Q4 2014 | $60,001,000 | -1.5% | 1,367,386 | +27.1% | 0.02% | -5.9% |
| Q3 2014 | $60,886,000 | +117.2% | 1,075,728 | +72.2% | 0.02% | +112.5% |
| Q2 2014 | $28,037,000 | -9.3% | 624,579 | -1.2% | 0.01% | -11.1% |
| Q1 2014 | $30,919,000 | – | 632,419 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 437,512 | $31,772,000 | 2.80% |
| RTW INVESTMENTS, LP | 1,373,284 | $99,728,000 | 2.06% |
| Rock Springs Capital Management LP | 1,028,109 | $74,661,000 | 1.88% |
| Privium Fund Management B.V. | 112,727 | $8,186,000 | 1.81% |
| Avidity Partners Management LP | 869,000 | $63,107,000 | 1.31% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 525,100 | $38,133,000 | 1.16% |
| Boxer Capital, LLC | 200,000 | $14,524,000 | 0.75% |
| SECTOR GAMMA AS | 46,221 | $3,357,000 | 0.73% |
| FEDERATED HERMES, INC. | 3,987,728 | $289,589,000 | 0.65% |
| EMERALD ADVISERS, LLC | 223,952 | $16,263,000 | 0.62% |